glp-1 agonists australia Supporting patients through agonist cessation effects GLP-1 Agonists Weight Loss Drugs
Description
5863 Although some of the effects of ER stress are tissue-specific, there are some commonalities in the damage to insulin signaling
Diabetes 60(12):31033109 Yanagimachi T, Fujita Y, Takeda Y et al (2016) Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (130) expression is upregulated in diabetes and PEGylated GIP(130) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice
Dulaglutide as a demethylating agent to improve the outcome of breast cancer
A meta-analysis of seven placebo-controlled cardiovascular outcomes trials found no increased risk of either acute pancreatitis or pancreatic cancer with GLP-1 RA treatment (Peto OR: 1.05, 95% CI 0.78, 1.40), 70 providing reassurance evidence against this concern in high-risk populations
Bettadapura et al., 2024
Danuglipron (Pfizer) is another oral GLP-1 currently in phase 2 trials, and CT-996 (Carmot Therapeutics) is in phase 1 trials
